Supplementary Figure S9 from Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Abstract

<p>Supplementary Figure S9 provides an overview of the mechanisms by which EVT801 exerts its anti-tumor effects</p>